ALPHA-1 antitrypsin affects U0126-induced cytotoxicity in colon cancer cell line (HCT116)
- Authors: Ljujic M.1, Mijatovic S.2, Bulatovic M.Z.2, Mojic M.2, Maksimovic-Ivanic D.2, Radojkovic D.1, Topic A.3
-
Affiliations:
- Institute of Molecular Genetics and Genetic Engineering
- Institute for Biological Research “Sinisa Stankovic”
- Institute of Medical Biochemistry, Faculty of Pharmacy
- Issue: Vol 50, No 1 (2016)
- Pages: 153-156
- Section: Short Communications
- URL: https://journals.rcsi.science/0026-8933/article/view/162539
- DOI: https://doi.org/10.1134/S002689331601012X
- ID: 162539
Cite item
Abstract
Alpha-1-antitrypsin (AAT), an acute phase protein, is the principal circulatory anti-protease. This multifunctional protein is encoded by the SERPINA1 gene. Although AAT was recognised as a potential tumour marker, its role in cancer biology remains unknown. Given that it has been demonstrated that AAT has an anti-apoptotic property against non-malignant cells, we aimed to investigate whether AAT affects apoptosis in a colon cancer cell line (HCT116). The presence of AAT in the HCT116 cell culture antagonized cytotoxicity of blockers of MEK1/2, PI3K/Akt pathways as well as NF-κB. The dominantly recovered cell viability was observed in the co-treatment with MEK1/2 inhibitor U0126. In addition, it was revealed that AAT almost completely abolished U0126-induced apoptosis through maintenance of the autophagy process. Our study revealed for the first time that the observed cyto-protection triggered by AAT was accompanied by sustained autophagy which opposed apoptosis. These results may contribute to understanding of the role of AAT in cancer development and evaluation of efficacy of cancer therapy.
About the authors
M. Ljujic
Institute of Molecular Genetics and Genetic Engineering
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
S. Mijatovic
Institute for Biological Research “Sinisa Stankovic”
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
M. Z. Bulatovic
Institute for Biological Research “Sinisa Stankovic”
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
M. Mojic
Institute for Biological Research “Sinisa Stankovic”
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
D. Maksimovic-Ivanic
Institute for Biological Research “Sinisa Stankovic”
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
D. Radojkovic
Institute of Molecular Genetics and Genetic Engineering
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
A. Topic
Institute of Medical Biochemistry, Faculty of Pharmacy
Author for correspondence.
Email: aleksandra.topic1@gmail.com
Serbia, Belgrade
Supplementary files
